Literature DB >> 12856382

Efficacy of dichloroacetate as a lactate-lowering drug.

Peter W Stacpoole1, Nelamangala V Nagaraja, Alan D Hutson.   

Abstract

Dichloroacetate (DCA) decreases blood, cerebral spinal fluid, and intracellular lactate concentrations by activating the mitochondrial pyruvate dehydrogenase enzyme complex. The authors reviewed the efficacy of this investigational drug in the treatment of acquired or congenital forms of lactic acidosis from data in 40 English-language publications. The hypolactatemic effect of DCA occurs over a broad range of pretreatment lactate concentrations and is directly related to the baseline lactate level. The maximum lactate-lowering effect of the drug is dependent on its dose but independent of time following its administration. Recent clinical studies of acquired lactic acidosis suggest that DCA could be rapidly effective in reducing this risk factor of mortality in patients with mild hyperlactatemeia.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 12856382

Source DB:  PubMed          Journal:  J Clin Pharmacol        ISSN: 0091-2700            Impact factor:   3.126


  55 in total

1.  Two dichloric compounds inhibit in vivo U87 xenograft tumor growth.

Authors:  Dmitriy Ovcharenko; Catrina Chitjian; Alex Kashkin; Alex Fanelli; Victor Ovcharenko
Journal:  Cancer Biol Ther       Date:  2019-06-24       Impact factor: 4.742

2.  Metabolic-targeted Combination Therapy With Dichloroacetate and Metformin Suppresses Glioblastoma Cell Line Growth In Vitro and In Vivo.

Authors:  Laura Korsakova; Jan Aleksander Krasko; Edgaras Stankevicius
Journal:  In Vivo       Date:  2021 Jan-Feb       Impact factor: 2.155

3.  DCA promotes progression of neuroblastoma tumors in nude mice.

Authors:  Benedikt Feuerecker; Christof Seidl; Sabine Pirsig; Gernot Bruchelt; Reingard Senekowitsch-Schmidtke
Journal:  Am J Cancer Res       Date:  2015-01-15       Impact factor: 6.166

4.  Effects of chlorinated acetates on the glutathione metabolism and on glycolysis of cultured astrocytes.

Authors:  Maike M Schmidt; Astrid Rohwedder; Ralf Dringen
Journal:  Neurotox Res       Date:  2010-07-14       Impact factor: 3.911

5.  Silencing gastrin-releasing peptide receptor suppresses key regulators of aerobic glycolysis in neuroblastoma cells.

Authors:  Eric J Rellinger; Carmelle Romain; SunPhil Choi; Jingbo Qiao; Dai H Chung
Journal:  Pediatr Blood Cancer       Date:  2015-01-28       Impact factor: 3.167

6.  Metabolic response of glioma to dichloroacetate measured in vivo by hyperpolarized (13)C magnetic resonance spectroscopic imaging.

Authors:  Jae Mo Park; Lawrence D Recht; Sonal Josan; Milton Merchant; Taichang Jang; Yi-Fen Yen; Ralph E Hurd; Daniel M Spielman; Dirk Mayer
Journal:  Neuro Oncol       Date:  2013-01-17       Impact factor: 12.300

7.  Cytometric assessment of DNA damage by exogenous and endogenous oxidants reports aging-related processes.

Authors:  Hong Zhao; Toshiki Tanaka; H Dorota Halicka; Frank Traganos; Miroslaw Zarebski; Jurek Dobrucki; Zbigniew Darzynkiewicz
Journal:  Cytometry A       Date:  2007-11       Impact factor: 4.355

8.  Mitaplatin, a potent fusion of cisplatin and the orphan drug dichloroacetate.

Authors:  Shanta Dhar; Stephen J Lippard
Journal:  Proc Natl Acad Sci U S A       Date:  2009-12-10       Impact factor: 11.205

9.  Dichloroacetate induces apoptosis and cell-cycle arrest in colorectal cancer cells.

Authors:  B M Madhok; S Yeluri; S L Perry; T A Hughes; D G Jayne
Journal:  Br J Cancer       Date:  2010-05-18       Impact factor: 7.640

10.  Phase 1 trial of dichloroacetate (DCA) in adults with recurrent malignant brain tumors.

Authors:  E M Dunbar; B S Coats; A L Shroads; T Langaee; A Lew; J R Forder; J J Shuster; D A Wagner; P W Stacpoole
Journal:  Invest New Drugs       Date:  2013-12-03       Impact factor: 3.850

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.